

## Summary of Utilization Management (UM) Program Changes

March 2024

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Xdemvy</i>	lotilaner	<p>For the treatment of Demodex blepharitis.</p> <p>Criteria requires:</p> <ol style="list-style-type: none"> <li>1) Diagnosis of Demodex blepharitis;</li> <li>2)] Patient exhibits one of the following signs of Demodex infestation: a) Collarettes, b) Eyelid margin erythema, or c) Eyelash anomalies (e.g., eyelash misdirection);</li> <li>3) Patient is experiencing symptoms or architectural changes associated with Demodex infestation (e.g., burning, tearing, itching, foreign body sensation, eyelashes missing, eyelashes growing inward);</li> <li>4) Trial and inadequate response to tea tree-oil;</li> <li>5) Prescribed by or in consultation with one of the following: a) Ophthalmologist or b) Optometrist</li> </ol>	New	4/1/2024
<i>Mounjaro in GLP-1 Agonists</i>	tirzepatide	<p>For the treatment of Type 2 diabetes mellitus</p> <p>Initial criteria will align with the criteria for Byetta, Bydureon, and Rybelsus.</p> <p>An additional change: If patient has severe uncontrolled diabetes (as defined as 1.5% above goal per ADA guidelines) at diagnosis, and thus unlikely to achieve control with a single drug, this drug can be approved for initial treatment. This is an update from the previous HgA1c value of 8.5% or higher to allow approval.</p>	Update	4/1/2024
<i>All formulary GLP-1 Agonists:</i> <i>Byetta</i> <i>Bydureon</i> <i>Ozempic</i> <i>Rybelsus</i> <i>Trulicity</i> <i>Victoza</i>	exenatide exenatide semaglutide semaglutide dulaglutide liraglutide	<p>One change: If patient has severe uncontrolled diabetes (as defined as 1.5% above goal per ADA guidelines) at diagnosis, and thus unlikely to achieve control with a single drug, this drug can be approved for initial treatment. This is an update from the previous HgA1c value of 8.5% or higher to allow approval.</p>	Update	4/1/2024